PELL BMT
沛爾生技醫藥股份有限公司
PELL BMT is a Taiwan TWSE-listed biotechnology company; its most advanced asset is PL001 (Phase 1 / Phase 2; active not recruiting, Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Large B-cell Lymphoma; Follicular Lymphoma Grade 3A; Follicular Lymphoma Grade 3B), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| PL001 | — | Phase 1 / Phase 2; active not recruiting | Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Large B-cell Lymphoma; Follicular Lymphoma Grade 3A; Follicular Lymphoma Grade 3B | Taiwan | 2026-10-09 | Trial registry |
| PP011 | — | Phase 1 trial in healthy participants authorized | Rheumatoid arthritis program; trial in healthy participants | China | 2026-06-02 | Company disclosure |
| PL002 | — | — | — | — | — | Company disclosure |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.